Redefining the Future of Cancer Treatment

We are united around our mission to redefine the future of cancer treatment. Our goal is to help people facing cancer live longer, better lives. Our hope is fueled by the dream of a future free from cancer.

Unlocking hope

Addressing the unmet medical needs of cancer patients

Today, our oncology researchers passionately strive to turn cancers into manageable chronic conditions or even curable diseases.

Tomorrow, our hope is fueled by the dream of a future free from cancer. We are determined to shift the treatment paradigm of cancer.

The urgency for effective, broadly accessible treatment options and novel therapies is paramount, as the outlook for patients is often grim, with survival measured in months rather than years. That’s what fuels our ambition to redefine the future of cancer treatment.

SPEED

Speed is critical for cancer patients who cannot afford to wait to receive treatment

URGENCY

Urgent need for effective, broadly accessible treatment options and novel therapies is paramount

Our focus in oncology

Delivering more years of live and improving the quality of life

Personalized, decentralized

Our innovative approach to CAR-T manufacturing near the point-of-care

Galapagos’ decentralized, innovative point-of-care CAR-T manufacturing platform consists of a proprietary end-to-end xCellit™ workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control (QC) testing and release strategy.

The combination of these three core components allows for the administration of a fresh product, a median vein-to-vein time of 7 days (i.e. the time between T-cell collection and CAR-T infusion), and providing greater physicians oversight throughout the process.

How Galapagos’ decentralized, innovative point-of-care CAR-T manufacturing platform can move the needle for cancer patients

Through decentralized manufacturing, complex logistics and cryopreservation of the cells can be avoided, and the average vein-to-vein time can be drastically reduced from up to months for currently approved CAR-T therapies to median 7 days with our CAR-T candidates currently observed in our clinical trials. Discover how in the video!

Point-of-care manufacturing, close to patients

One of the three pillars of our point-of-care platform is a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon® Platform). Discover more about it!

Factsheet

Our commitment in oncology

Do you need everything in one place about our efforts in redefining the future of cancer treatments?

Pioneer with us in Oncology

This is your call for purpose!

Do you want to pioneer for patients in Oncology? Discover our vacancies!

Disease areas

More about our work in Immunology

We strive to accelerate innovation of transformational medicines that deliver more years of life and quality of life for patients and families living with cancer.

Partnerships

Work with us!

We combine internal and external innovation to add new capabilities, technologies and product candidates. Let’s start #PioneeringForPatients, together!

Galapagos Health

Explore our HCP Portal

Are you a healthcare professional? Are you looking for Galapagos’ medical education, product information or congress presence? Look no further!